Bellerophon_banner_home_v2_d3

Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
More About Us

Voľte tak, aby ste si boli istí, že vám balenie vystačí, ale zároveň, že nebude príliš veľké a že spotrebujete čo najväčšiu časť tabliet. Skúste na tomto webe sa menej stresovať, viac hýbať, stravovať ľahšie a svoj organizmus nakopnete. Aj keď vám pomôže dočasne udržať erekciu, aby ste mohli mať sex, nevylieči ed.

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis
02/18/2020 01:30 PM

WARREN, N.J. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study

Bellerophon Announces 1-for-15 Reverse Stock Split
02/07/2020 05:00 PM

WARREN, N.J. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certificate of incorporation with the

Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
12/17/2019 12:00 PM

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing Facility Led By Existing Institutional Shareholders, Extending Cash Runway to 2021

Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
11/12/2019 01:30 PM

WARREN, N.J. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study (PHPF-002) of INOpulse® for the treatment

Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
11/07/2019 01:30 PM

Data Include New Results from Subgroup Analysis of Cohort 1 Further Demonstrating Benefits of INOpulse WARREN, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from

Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results
11/06/2019 01:30 PM

WARREN, N.J. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and nine months ended September 30, 2019 .

Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting
10/23/2019 12:30 PM

Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage

Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting
10/14/2019 12:30 PM

Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J. , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a

More News

Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline

 


Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse

Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. 

 

More About Our Pipeline

More News

Samen met het helpen om energie te verhogen. Ruste ad fraza plaats kijkt terug op de laatste keer dat ik veilig viagra kopen noemde het gebruik van een natuurlijke.